**ORIGINAL ARTICLE** 



### INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES

Published by JK Welfare & Pharmascope Foundation J

Journal Home Page: <u>https://ijrps.com</u>

### Development and validation of indocyanine green assay in human plasma using High-Performance Liquid Chromatography with PDA detector

Sumith K Mathew, Blessed Winston A, Aswathy Mathew, Jeana Jacob, Ratna Prabha, Binu Susan Mathew\*

Department of Pharmacology and Clinical Pharmacology, Clinical Pharmacology Unit, Christian Medical College, Vellore – 632004, Tamil Nadu, India

Article History:	ABSTRACT (Deck for updates)
Received on: 18.11.2018 Revised on: 09.03.2019 Accepted on: 12.03.2019	A robust and economical assay for routine determination of indocyanine green pharmacokinetics was developed and validated using high-perfor- mance liquid chromatography with a photodiode array detector. Plasma specimens from critically ill patients and those with hepatitis on various co-
Keywords:	medications were used as blanks for validation of this assay. Extraction of indocyanine green was performed by simple protein precipitation with ace-
HPLC assay, Indocyanine green, Photodiode array detec- tor	tonitrile, and the supernatant was separated using an octadecyl column with detection at 784 nm. Blanks were found to have no interference for 40 blanks of patients who were on 56 different medications. The precision for LLOQ ( $0.5 \ \mu g/ml$ ) as determined by the percentage coefficient of variation was 1.19. Stability of plasma calibration standards and stock were determined over a period of 61 days, and ICG was found to be stable for 20 days. Stability of whole blood specimens containing ICG was determined at 4°C for a period of 4 hours.

\* Corresponding Author

Name: Binu Susan Mathew Phone: +91-9944423760 Email: binusphilip@gmail.com

ISSN: 0975-7538 DOI: <u>https://doi.org/10.26452/ijrps.v10i2.373</u>

Production and Hosted by

IJRPS | <u>https://ijrps.com</u> © 2019 | All rights reserved.

#### INTRODUCTION

Indocyanine green (ICG) is a cyanine dye given intravenously, the concentration-time profile of which is determined to assess the cardiac output (Iijima *et al.*, 1997), liver function (De Gasperi *et al.*, 2016) and is used for ophthalmic angiography (Agrawal *et al.*, 2013). Global prevalence of cirrhosis is 4.5% to 9.5% of the general population as reported by Melato M *et al.*, Graudal N and Lim YS (Graudal *et al.*, 1991; Melato *et al.*, 1993; Lim and Kim 2008). ICG plasma disappearance rate can be used to assess the dynamic liver function in critically ill patients (Halle *et al.*, 2014).

Spectrophotometric methods are commonly used to determine the concentrations of ICG in plasma. But the specificity of this method is questioned (Rappaport and Thiessen 1982; Grasela *et al.*, 1987) and measuring ICG concentrations in critically ill patients who are on multiple medications may further compromise the specificity of the spectrophotometric assay.

Rappaport *et al.*, reported that ICG in plasma was stable when stored for 10 weeks at 6°C (Rappaport and Thiessen 1982). In another study performed by Awni WM *et al.*, the ICG in plasma was found to be stable at room temperature for up to 24 hours (Awni and Bakker 1989). In another study, March et.al showed that the concentration of ICG decreased significantly over a period of 1 week after storage in -20°C (March *et al.*, 1994; Vicient *et al.*, 2017) and this instability of ICG in plasma specimens was attributed to the preservative effect of the anticoagulant that was used in these specimens. Elimination of ICG follows an exponential curve, and the half-life of ICG is  $\sim 150 - 180$  seconds (Henschen *et al.*, 1993). This implies the need for multiple blood specimen collection over a period of 30 minutes to determine liver function. The difficulty in the immediate transfer of whole blood specimens and its processing mandates the need for stability of ICG in whole blood specimens.

The purpose of this study was to develop and validate an HPLC assay for ICG in human plasma which is simple, accurate, precise, highly selective, sensitive, and robust whilst being economical and a feasible option for clinical use. To improve the selectivity of ICG detection, wavelengths of more than 700 nm was screened. This assay would be routinely utilized in patients with liver pathology for studying the plasma disappearance rate of ICG prior to surgical intervention. The stability of ICG in plasma at different storage conditions was also determined.

#### **MATERIALS AND METHODS**

#### **Reagents and chemicals**

ICG was purchased from Adooq Bioscience, USA. Voriconazole (internal standard) and acetonitrile were purchased from Sigma Aldrich, and ammonium acetate was purchased from Fisher Scientific (Mumbai, India). ICG, acetonitrile and ammonium acetate were HPLC grade. Double distilled water was prepared in the laboratory from Milli-Q Gradient water purification system.

#### Instrumentation and Chromatographic Conditions

HPLC with Photodiode array detector (Shimadzu Quaternary Prominence I LC-2030C plus) was used for the assay development. Separation was carried out with Luna®  $5\mu$ m C18(2) column of dimensions  $250 \times 4.6$  mm with a particle size of 5  $\mu$ m and pore size of 100 Å. An isocratic method was used with a mixture of 20 mM ammonium acetate and acetonitrile as the mobile phase at the ratio of 55:45, detected at 784 nm for ICG and 254 nm for the internal standard. The column was maintained at 30°C, and the auto-sampler was maintained at ambient temperature throughout the analysis.

#### Calibration curve standards and quality controls

Two separate primary stocks (1 mg/ml) in methanol was prepared for the calibration standards and the quality controls (QC). The primary stock of ICG is further diluted in methanol (1:10) to produce the secondary stock, which is again diluted in methanol (1:10) to produce the tertiary stock. Calibrators and quality controls were obtained by dilution from either primary or secondary or tertiary stocks in plasma. Calibrators included 20, 15, 10, 7.5, 2.5, 1.0, 0.75, 0.5 and 0.1  $\mu$ g/ml and quality controls included 12.5 (high), 5 (Medium) and 0.8 (low)  $\mu$ g/ml.

#### **Extraction method**

ICG was extracted by a simple protein precipitation method. Into 300  $\mu$ l of plasma, 30  $\mu$ l of internal standard (1  $\mu$ g/ $\mu$ l) was added and precipitated with 400  $\mu$ l of acetonitrile. The solution was vortexed and centrifuged at 9447 g for 5 min. 50  $\mu$ l of supernatant was injected into the system for the determination of ICG concentration.

#### Validation of ICG assay

The validation of the assay was based on the guidelines issued under the United States, Food and Drugs Administration guidance for a bioanalytical method of validation (Guidances (Drugs)).

#### Selectivity

Six zero standards were prepared from blood specimens of patients with liver cirrhosis, hepatitis and other hospital inpatients by spiking 30  $\mu$ l of the internal standard. Serum specimens of 40 patients on various co-medications were used as blank specimens to check for interferences at the retention time of ICG and internal standard. The list of co-medications used by the 40 patients is listed in Table 1.

#### Accuracy, bias and precision of QC

The low, medium and high concentration quality controls were compared against the calibration curve to determine the accuracy and precision of ICG extraction. For this, five different extractions were performed from one sample, for each of the QC's on day 0 and another five different extractions were performed on day 2. The days were counted from the time of preparation of the QC. Same calibration standards used on day 0 were used on day 2. One injection was performed for each extract. The accuracy of the assay was determined by estimating the bias for each extraction measured on the same day, in comparison to the true concentration that was spiked. The precision of the five extracts of a single concentration was also determined.

$$Mean \ concentration = \frac{\sum_{\underline{n}}^{x} = 1 \ Concentration \ (n)}{x}$$

$$Bias = \frac{\sum_{\underline{n=1}}^{x} \{Observed \ value \ (n) - Expected \ value \}/ Expected \ value}{x} \times 100$$
Standard deviation

$$Precision = \frac{Standard\ deviation}{Mean} \times 100$$

Inter-day accuracy and precision were also calculated for Day 0 and day 2 for each of the concentrations.

Reinjection reproducibility was determined by estimating the precision of low, medium and high QCs, by repeatedly injecting five times from the same extracted sample.

#### Accuracy and precision for LLOQ and ULOQ

The intra-day bias and precision of LLOQ and ULOQ were estimated by comparing 5 different extractions of LLOQ and ULOQ, in the same batch and on the same day.

#### Linearity of the calibration curve

The linearity of the calibration curve was validated on six different days with calibration curves made using newly spiked calibration standards on each day. Two different primary stocks were used to prepare the standards and quality controls respectively over these 6 days.

#### **Process efficiency**

The process efficiency of extraction was calculated for low QC and high QC as follows;

 $Process \ efficiency \ (\%) = \frac{Pre \ extraction \ ratio}{Stock \ solvent \ extraction \ ratio} \times 100$ 

Pre-extraction ratio was the ratio of chromatogram area of the drug to the internal standard with the usual extraction procedure. Stock solvent extraction ratio was obtained by mixing 300  $\mu$ l of methanol stock containing 0.8  $\mu$ g/ml and 12.5  $\mu$ g/ml of ICG with 30  $\mu$ l of 1 $\mu$ g/ $\mu$ l internal standard. It was performed with five different extractions of low QC and high QC.

#### Stability of ICG

#### Stability in -20 degree Celsius

Both the stock and the plasma specimens were stored in -20°C, and were extracted on day 9, 17, 20, 41 and 61. Plasma specimens of concentration 8 and  $20_{\mug}/ml$  were used. The concentrations measured on each of the days were compared against the freshly prepared plasma calibration standards prepared on the day of analysis.

#### **Freeze-Thaw cycles**

Plasma specimens of concentration 8 and  $20_{\mu}g/ml$  were used. Four freeze-thaw cycles were performed over a period of 5 days from the preparation of calibration standards. The concentrations measured after each freeze-thaw cycle was compared against the freshly prepared plasma calibration standards prepared on the day of analysis.

**Stability of blood specimen in the refrigerator at 4°C:** To determine the stability of ICG in the refrigerator, blood specimens were collected from a healthy volunteer and spiked with ICG with two different concentrations and mixed gently with the blood mixer. Plasma was separated at 0 hr, 0.5 hr, 1.0 hr, 2.0 hr and 4.0 hr respectively from the spiked blood samples stored at 4°C and was analyzed. All the extractions were performed in duplicate, and the mean concentration was determined. The concentrations obtained after storage of blood specimens for prolonged intervals in the refrigerator was compared with the immediately separated plasma concentration.

#### **Benchtop stability**

Benchtop stability was determined over a period of 5 hours at room temperature. New plasma quality controls were prepared and were compared against newly prepared calibration standards.

#### Autosampler stability

The stability of extracted QC specimens in the autosampler was evaluated against calibration standards, which were estimated immediately after extraction. The bias and precision of low, medium and high-quality controls were estimated over a period of 48 hours post extraction.

#### RESULTS

The total run time of the assay was 13 min with elution of ICG at 11.0 min and internal standard at 7.35 min respectively. The chromatogram is shown in figure 1. The optimal wavelengths for detection of ICG and standard internal detection were determined to be 784 nm and 254 nm respectively as the chromatogram had minimum baseline fluctuation and the blanks were devoid of peaks at the corresponding retention times for the drug and internal standard.

**Selectivity:**As blanks, 40 patient specimens containing 56 different drugs were tested. No peaks were detected for these blank specimens between the 6 to 11 min chromatogram run times. The signal: noise ratio of Lower Limit of Quantification  $(0.1 \ \mu g/ml)$  was 8.5.

# Accuracy and precision for QC's, LLOQ and ULOQ

The intra-day and inter-day bias and precision of the quality controls are reported in Table 2. The precision (CV%) of 5 injections of low, medium and high QCs from the same extract were 0.35, 0.38 and 0.27 respectively.

LLOQ and ULOQ was determined to be 0.5  $\mu$ g/ml and 20  $\mu$ g/ml respectively. The signal to noise ratio of LLOQ was 13.09 for ICG. The same-day and inter-day bias and precision of 5 different extractions of LLOQ and ULOQ were within acceptable limits. The accuracy and precision for QC's, LLOQ and ULOQ are shown in Table 2.



Figure 1: Typical Chromatogram of A. ULOQ, B. LLOQ, C. Internal standard, and D. Blank Table 1: Co-medications screened in patients to determine the selectivity of the assay for ICG

Anti-infective drugs		
Cefoperazone	Meropenem	Colistimethate sodium
Sulbactam	Vancomycin	Norfloxacin
Fluconazole	Posaconazole	Caspofungin
Clindamycin	Tigecycline	Metronidazole
Ciprofloxacin	Crystalline Penicillin	Amikacin
Other drugs		
Adrenaline	Noradrenaline	Ephedrine Hydrochloride
Ascorbic Acid	Succinylated Gelatin	Thiamine
Hydrocortisone	Filgrastim	Propofol
Midazolam	Pantoprazole	Vecuronium
Suxamethonium Chloride	Ferrous fumarate	Enoxaparin sodium
Acetaminophen	Ondansetron	Tramadol
Furosemide	Spironolactone	Metoprolol
Acetazolamide	Hydrochlorothiazide	Lansoprazole
Ipratropium	Aspirin	Salbutamol
Heparin	Clonidine	Atorvastatin
Lamotrigine	Levosulpiride	Levetiracetam
Amiodarone	Metoclopramide	Risperidone
Propranolol	Amlodipine	Theophylline
Clozapine	Folic Acid	-

Table 2: Accuracy and precision of low, medium and high QC's, LLOQ and ULOQ

	Mean	Bias%	Precision (CV %)
Intra-day			
Low QC	0.84	4.91	1.88
Medium QC	5.05	0.95	2.73
High QC	12.09	-3.26	3.37
LLOQ	0.57	13.51	1.19
ULOQ	18.45	-7.75	0.006
Inter-day			
Low QC	0.84	4.78	1.97
Medium QC	4.80	-4.00	7.51
High QC	12.14	-2.88	3.50

Low QC = 0.80  $\mu$ g/ml, medium QC = 5.0  $\mu$ g/ml, high QC = 12.50  $\mu$ g/ml, LLOQ = 0.50  $\mu$ g/ml, ULOQ = 20  $\mu$ g/ml

	Bias		
Conc (µg/ml)	8	20	
Stability of plasma standards when stored at -20°C			
Day 9	5.24	-1.51	
Day 17	-6.19	-8.64	
Day 20	-4.79	-2.55	
Day 41	-17.66	-8.33	
Day 61	-30.07	-26.30	
Stability of standard stock when stored at -20°C			
Day 61	-3.11	8.94	

			_		
Tahla 2. Stahility	v of difforont r	lacma ctandard	concontrations	over a neriod	of 61 dave
Table 5. Stability	<sup>o</sup> or unierent p	nasina stanuaru	concenti ations	over a periou	UI UI UAYS

Table 4: Measured concentrations of ICG over a period of 5 consecutive days to determinefreeze-thaw cycle stability

Freeze-Thaw cycle	8 μg/ml (% agreement)	20 μg/ml (% agreement)
0	8.61	20.4
1	8.81 (102.2)	20.22 (99.1)
2	8.49 (98.5)	20.12 (98.6)
3	8.68 (100.8)	20.05 (98.3)
4	8.36 (97.1)	20.55 (100.7)

#### Linearity of the calibration curve

The calibration curve was fitted using quadratic least square regression ( $y = ax^2 + bx + c$ ) of the peak ratios (drug area/ internal standard area) ( $r^2 = 0.999$ ) over the concentration range of 0.1 to 20 µg/ml, where y is the concentration in µg/ml and x is the peak ratio.

#### **Process efficiency**

The extraction process efficiency was 117.2% and 104.1% for low QC and high QC respectively.

Stability of stock and plasma specimens at -20 degree Celsius: The plasma specimens of concentration 8 and 20  $\mu$ g/ml prepared from the stored primary stock was compared against the newly prepared primary stock calibration standards on day 20. The agreement between day 0 and day 61 for the primary stock for low, medium and high concentrations were 96.9 %, 108.9 % and 99.9 % respectively.

For the plasma specimens stored at -20°C, the agreement against the freshly prepared calibration curve (prepared from the fresh primary stock) was 69.9 % and 73.7 % respectively for 8 and 20 µg/ml on Day 61.

**Benchtop stability:** Plasma standard concentrations 8 and 20  $\mu$ g/ml were extracted immediately

after thawing and analyzed. The same plasma specimens were stored for 1 hour, 2.5 hour and 5 hours on the benchtop and then analyzed. No degradation was observed when stored over a period of 5 hours at room temperature.

Freeze-Thaw cycles: The average estimated concentration for 8 and 20  $\mu g/ml$  obtained over the

entire study duration of 5 consecutive days is described in Table 4.

## Stability of blood specimen in the refrigerator at 4°C

The precision for low concentration (3.90  $\mu$ g/ml) was 1.64 %, and high concentration (18.02  $\mu$ g/ml) was 3.34 % respectively for whole blood ICG specimens stored in refrigerator over a period of 4 hours.

#### Autosampler stability

The agreement of fresh spiked concentrations of 8 and 20  $\mu$ g/ml with specimens stored in the autosampler for 48 hours post extraction was 97.5%, 101.0% and 100.3%.

#### DISCUSSION

The method is validated in critically ill patients and those with hepatitis who were on co-medications mentioned in table 1. The extraction method is a modification of the method published by Vicient *et al.*, (Vicient *et al.*, 2017). The run time of the developed assay is short (13 minutes) and the chromatogram obtained is good (number of theoretical plates calculated by tangent line method was 7460 and 7496 and tailing factor was 1.2 and 1.1 for internal standard and ICG respectively), for routine therapeutic drug monitoring purpose. Process efficiency of ICG assay is more than 100% and the patient blank specimens examined for the selectivity of the assay for ICG is found to be reliable.

ICG is stable in plasma at room temperature over a period of 5 hours, and this finding is in agreement with Awni WM *et al.*, and Rappaport P. L *et al.*, (Rappaport and Thiessen 1982; Awni and Bakker 1989). Contrary to the findings of March C *et al.*,

(March *et al.*, 1994), our study has demonstrated the stability of ICG plasma specimens over a period of 20 days in -20°C. ICG is also found to be stable in whole blood for a period of 4 hours when stored at 4°C. Stability of ICG in plasma, when stored at different temperatures for varying periods of time, helps conduct the ICG pharmacokinetic tests in settings like intensive care units.

#### CONCLUSION

The assay developed is economical, easy to perform, accurate, sensitive, highly selective and robust to determine the concentration-time profile of ICG in liver cirrhosis patients and this assay could even be used in critically ill patients who may be on many co-medications. The stock prepared in methanol and the plasma calibration standards are stable over a period of 20 days when stored at -20°C. The whole blood specimens containing ICG are stable when stored at 4°C for 4 hours.

#### Acknowledgement

The authors are grateful to Mr Elumalai and Ms Lavanya for the technical help in the development of the assay.

#### REFERENCES

- Agrawal, R.V. *et al.*, 2013. Indocyanine green angiography in posterior uveitis. *Indian Journal of Ophthalmology* 61(4), pp. 148–159. doi: 10.4103/0301-4738.112159.
- Awni, W.M. and Bakker, L.J. 1989. Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography. *Clinical Chemistry* 35(10), pp. 2124–2126.
- De Gasperi, A. *et al.*, 2016. Indocyanine green kinetics to assess liver function: Ready for a dynamic clinical assessment in major liver surgery? *World Journal of Hepatology* 8(7), pp. 355–367. doi: 10.4254/wjh. V8. i7.355.
- Grasela, D.M. *et al.*, 1987. Experimental impact of assay-dependent differences in plasma indocyanine green concentration determinations. *Journal of Pharmacokinetics and Biopharmaceutics* 15(6), pp. 601–613. doi: 10.1007/BF01068415.
- Graudal, N. *et al.*, 1991. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. *Journal of Internal Medicine* 230(2), pp. 165– 171.
- Guidances (Drugs). Available at: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm [Accessed: 16 April 2018].

- Halle, B.M. *et al.*, 2014. Indocyanine green plasma disappearance rate as dynamic liver function test in critically ill patients. *Acta Anaesthesiologica Scandinavica* 58(10), pp. 1214–1219. doi: 10.1111/aas.12406.
- Henschen, S. *et al.*, 1993. Determination of plasma volume and total blood volume using indocyanine green: a short review. *Journal of Medicine* 24(1), pp. 10–27.
- Iijima, T. *et al.*, 1997. Cardiac output and circulating blood volume analysis by pulse dye-densitometry. *Journal of Clinical Monitoring* 13(2), pp. 81–89. doi: 10.1023/A:1007339924083.
- Lim, Y.-S. and Kim, W.R. 2008. The global impact of hepatic fibrosis and end-stage liver disease. *Clinics in Liver Disease* 12(4), pp. 733–746, vii. doi: 10.1016/j.cld.2008.07.007.
- March, C. *et al.*, 1994. Stability of indocyanine green in human serum stored at -20 and -70 degrees C. *Therapeutic Drug Monitoring* 16(6), pp. 588–591.
- Melato, M. *et al.*, 1993. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. *Zentralblatt Fur Pathology* 139(1), pp. 25–30.
- Rappaport, P.L. and Thiessen, J.J. 1982. High-pressure liquid chromatographic analysis of indocyanine green. *Journal of Pharmaceutical Sciences* 71(2), pp. 157–161.
- Vicient, L. *et al.*, 2017. Simple Method for the Determination of Indocyanine green in human plasma by High-Performance Liquid Chromatography with Ultraviolet Detector. *Journal of Research Analytica* 3(2), pp. 37–41.